ProQuad [Measles, Mumps, Rubella, and Varicella (Oka/Merck) Virus Vaccine Live]

DECEMBER 01, 2005

Merck & Co Inc (Whitehouse Station, NJ) recently received FDA approval for the combination vaccine ProQuad for simultaneous vaccination against measles, mumps, rubella (German measles), and varicella (chickenpox) in children 12 months to 12 years of age. The product also may be used in this patient group if a second dose of measles, mumps, and rubella vaccine is to be administered. Patients should receive a 0.5-mL single dose of ProQuad subcutaneously. At least 1 month should elapse between a dose of a measles-containing vaccine and a dose of ProQuad. If a second dose of varicella-containing vaccine is required, at least 3 months should elapse. For more information, visit www.merck.com.



SHARE THIS SHARE THIS
0

Conference Coverage

Check back here regularly for live conference coverage from the American Academy of Pain Medicine and the upcoming American Pharmacists Association Meeting and Expo. 


Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.